Oragenics Inc., a biotechnology company focused on developing treatments for brain-related illnesses, faces financial challenges despite its innovative approach and commitment to advancing its pipeline of potential treatments.

Oragenics Inc, a biotech company, experienced a dramatic week in the stock market, with its shares surging by 138% before plummeting by 55% due to a preferred stock offering and subsequent market reaction.

Oragenics, Inc. is a biotechnology company making significant strides in treating brain-related illnesses, such as mild traumatic brain injury and Niemann Pick Disease Type C, with innovative treatments and a proprietary delivery method.

Oragenics, Inc. is a development-stage biotech company focused on treating brain-related illnesses and diseases, with a market capitalization of $4.17 million and a highly volatile stock price.